Gc Biopharma (006280) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, Gc Biopharma (006280) reported revenue of 1.99 trillion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
20251.99 trillion KRW69.1 billion KRW-29.7 billion KRW[source]
20241.68 trillion KRW32.1 billion KRW-42.6 billion KRW[source]
20231.63 trillion KRW34.4 billion KRW-19.8 billion KRW[source]
20221.71 trillion KRW81.3 billion KRW69.4 billion KRW[source]
20211.54 trillion KRW73.7 billion KRW136.9 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
20252.39 trillion KRW1.11 trillion KRW1.28 trillion KRW[source]
20242.22 trillion KRW975.9 billion KRW1.25 trillion KRW[source]
20232.10 trillion KRW846.3 billion KRW1.25 trillion KRW[source]
20221.94 trillion KRW692.8 billion KRW1.25 trillion KRW[source]
20211.93 trillion KRW700.2 billion KRW1.23 trillion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice